Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Mutation Based Classification of Endometrial Carcinomas for Improved Targeted Therapeutics
EF 2010-11
Résumé
Uterine cancer, also known as endometrial cancer, is the most common gynaecological cancer for Canadian women. In 2010, uterine cancer is ranked as the fourth most common type of women cancer, with approximately 4500 new cases being diagnosed yearly. Overall, uterine cancer is reported to have about an 80% survival rate over 5 years, although this statistic is somewhat deceiving. As the cancer changes with increasing severity and grade the survival rates drastically decrease, indicating there is a decreased response to current therapy. This results in many women undergoing ineffective, toxic treatments with negative side effects that heavily outweigh the short-term effects on the tumour. Therefore, there is an urgent need to better understand the molecular genetics of uterine cancers in order to assist medical professionals in providing personalized targeted therapy. Classification of uterine cancers is currently limited to microscopic analysis which divides tumours into two different cell subtypes. These tumours are then graded using international standards in order to determine appropriate surgical and adjuvant therapy. Unfortunately, this classification scheme is incomplete as it does not reflect the molecular differences that are known to exist within these cell type groups. Thus, the main goal of this project of is to use advances in genomic sequencing technology to identify specific genetic mutations in key cancer genes within uterine cancers. This information will provide a better understanding of the molecular complexity of these cancers, and will be used to classify tumour types based on mutational profiles and patient outcome. Importantly, results from this project will inform the development of new drugs to specifically target uterine tumour subtypes and form the basis for future research into personalized therapeutics for Canadian women living with uterine cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
226953
Name
McConechy Melissa K
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Mutation Based Classification of Endometrial Carcinomas for Improved Targeted Therapeutics
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Endometrial Carcinoma; Molecular Classification; Next Generation Sequencing; Oncogenes; Pathology; Somatic Mutations; Tumour Suppressors
Abstract
Uterine cancer, also known as endometrial cancer, is the most common gynaecological cancer for Canadian women. In 2010, uterine cancer is ranked as the fourth most common type of women cancer, with approximately 4500 new cases being diagnosed yearly. Overall, uterine cancer is reported to have about an 80% survival rate over 5 years, although this statistic is somewhat deceiving. As the cancer changes with increasing severity and grade the survival rates drastically decrease, indicating there is a decreased response to current therapy. This results in many women undergoing ineffective, toxic treatments with negative side effects that heavily outweigh the short-term effects on the tumour. Therefore, there is an urgent need to better understand the molecular genetics of uterine cancers in order to assist medical professionals in providing personalized targeted therapy. Classification of uterine cancers is currently limited to microscopic analysis which divides tumours into two different cell subtypes. These tumours are then graded using international standards in order to determine appropriate surgical and adjuvant therapy. Unfortunately, this classification scheme is incomplete as it does not reflect the molecular differences that are known to exist within these cell type groups. Thus, the main goal of this project of is to use advances in genomic sequencing technology to identify specific genetic mutations in key cancer genes within uterine cancers. This information will provide a better understanding of the molecular complexity of these cancers, and will be used to classify tumour types based on mutational profiles and patient outcome. Importantly, results from this project will inform the development of new drugs to specifically target uterine tumour subtypes and form the basis for future research into personalized therapeutics for Canadian women living with uterine cancer.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
McConechy, Melissa K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~